BioWorld

Sep. 8, 2004

View Archived Issues

Deal With Merck Potentially Worth $26M For TransTech

TransTech Pharma Inc. secured another partnership, courtesy of its platform technology, in a collaboration that could be worth at least $26 million to the 5-year-old firm. (BioWorld Today) Read More

MAP Series B Draws $30M For Pediatric Asthma Work

Read More

Sunesis, Biogen Idec In Cancer Deal Worth $21 Million Up Front

Read More

Vivus Launching Phase III With Female Sex Therapy

Read More

Other News To Note

Read More